Innovative Pharmaceutical Biotech Limited provided earnings guidance for the six months ending September 30, 2021. For the period, the company expects to record a profit attributed to equity shareholders of the Company for the six months ended 30 September 2021 in the range between HKD 100 million and HKD 200 million, compared to the loss of approximately HKD 93.5 million for the same period in 2020, which was mainly attributable to the non-cash item resulted from the completion of the modification of convertible bond during the period. The difference of the carrying value of the convertible bond and fair value of the liability component of the convertible bond at the completion was credited to the income statement.